@article{4d4852a816244a01b477412bd6c65cbd,
title = "Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne",
abstract = "Background Adverse changes in bone have been reported for patients undergoing high-dose, long-term (several years) isotretinoin therapy for disorders of cornification. The effect of short-term (4-5 months) therapy at the lower dose recommended for acne on bone development in younger, growing adolescent (12-17 years) patients has not been well studied. Objective The purpose of the study was to evaluate the effect of a standard, single course of isotretinoin (Accutane) therapy on bone mineral density (BMD) of the lumbar spine and hip in adolescents ages 12 to 17 years with severe, recalcitrant, nodular acne. Methods In this open-label, multicenter study, 217 adolescents (81 girls) with severe, recalcitrant, nodular acne were enrolled and treated with isotretinoin twice daily with food at the recommended total dose of approximately 1 mg/kg for 16 to 20 weeks. BMD in the lumbar spine and hip was measured at baseline and at the end of therapy by dual energy radiograph absorptiometry. Results There was no clinically significant mean change in BMD measured at the lumbar spine (+1.4%, range: -4.9% to +12.3%) or total hip (-0.26%, range: -11.3% to +15.0%). Hyperostosis was not observed in any patient. Typical effixcacy expected in the treatment of acne was observed. Conclusions A 16- to 20-week course of isotretinoin treatment at the recommended dose for severe acne has no clinically significant effect on lumbar spine and total hip BMD in the adolescent (12-17 years) population.",
author = "Digiovanna, {John J.} and Langman, {Craig B.} and Tschen, {Eduardo H.} and Terry Jones and Alan Menter and Lowe, {Nicholas J.} and Lawrence Eichenfield and Hebert, {Adelaide A.} and David Pariser and Savin, {Ronald P.} and Smith, {Stacy R.} and Michael Jarratt and David Rodriguez and Chalker, {Dan K.} and Steven Kempers and Mark Ling and Rafal, {Elyse S.} and Sabra Sullivan and Sewon Kang and Shah, {Leena P.} and Emily Wu and Julie Newhouse and Jonathan Pak and Eberhardt, {Douglas R.} and Bryce, {Graeme F.} and McLane, {John A.} and Michael Ondovik and Catherine Chin and Khoo, {Ko Chin} and Phoebe Rich",
note = "Funding Information: Disclosures: All coauthors were supported by Roche for this study. Dr DiGiovanna has received honoraria and travel support from Hoffmann-La Roche, and grant support from Hoffmann-La Roche and Allergan, companies with an interest in systemic retinoids for acne. Dr DiGiovanna has served as a consultant to Hoffmann-La Roche. In addition, Dr DiGiovanna has received honoraria, travel, and grant support from companies with an interest in other, general acne medications. Dr Langman has served as a consultant to Roche. Drs Tschen and Jones have received grant support from Allergan. Dr Menter has received grant support and been a consultant to Allergan. Dr Lowe has received research grants from Roche. Dr Eichenfield has received grant support from Roche. Drs Hebert and Pariser have no additional disclosures. Dr Savin has received grant support from Roche and Allergan. Dr Smith has received grant support from Hoffmann La Roche and Allergan, companies with an interest in systemic retinoids for acne. In addition, Dr Smith has received honoraria, travel, and grant support from companies with an interest in other, general acne medications. Dr Jarratt has no additional disclosures. Dr Rodriquez has received grant support from Hoffmann La Roche and honoraria, travel, and grant support from Allergan, companies with an interest in systemic retinoids for acne. In addition, Dr Rodriquez has received honoraria, travel, and grant support from companies with an interest in other, general acne medications. Dr Chalker has been a consultant for Roche and Arriva Pharmaceuticals, and owns stock in Genzyme and Wyeth. Dr Kempers has no additional disclosures. Dr Ling has received research grant support from Roche and Allergan; Roche speakers' bureau. Dr Rafal has received grant support from Roche and Allergan. Dr Rafal has received honoraria, travel, and grant support from companies with an interest in other, general acne medications. Dr Sullivan has received honoraria and travel support from Roche. Dr Kang has no additional disclosures. Drs Shah, Wu, Pak, Eberhardt, Bryce, McLane, Ondovik, Chin, and Khoo were employees of Roche. Dr Newhouse was a Roche postdoctoral fellow. Dr Rich has no additional disclosures. ",
year = "2004",
month = nov,
doi = "10.1016/j.jaad.2004.04.032",
language = "English (US)",
volume = "51",
pages = "709--717",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",
}